EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS - ENDO LAUNCHES NATESTO

US partner Endo has launched Trimel’s Natesto in the c US$2bn US testosterone replacement therapy (TRT) market. Natesto is being positioned as the first and only nasal gel for hypogonadism, and is highlighted for its lower associated risk of testosterone transference.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is marketed for HRT in Canada.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports

Acerus Pharmaceuticals (QB) (USOTC:ASPCF)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse Acerus Pharmaceuticals (QB)
Acerus Pharmaceuticals (QB) (USOTC:ASPCF)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse Acerus Pharmaceuticals (QB)